Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) http://www.etcbaltimore.com ... today that applications for AccelerateBaltimore™ (AB) 2015 program ... have a big idea?,” asked ETC’s President Deb ... it. AccelerateBaltimore helps you and your big idea ... weeks.” Interested game changers with “big ideas” ...
Breaking Biology Technology:Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies in ... guidance following,the recently announced acquisitions which will ... of plasma based products in China., ...
... AMES, Iowa, Oct. 16 Advanced Analytical Technologies,Inc. (AATI), ... production space,adding an additional 1200 ft2 of space to ... company occupies in Building 4 on the,ISU Research Park ... company will continue to occupy space in 2 building ...
... Radiation Therapy Trials to US ... Patients for First Time, HOUSTON, Oct. 16 The ... they have entered into a,collaboration to increase patient access to ... setting., The collaboration means patients receiving cancer care at ...
Cached Biology Technology:China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 2China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 3Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 3Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 4Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 5
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... A University of Oklahoma-led study has demonstrated that ancient ... The microbiomes from ancient people have broad reaching implications ... what good bacteria might have been lost as a ... aseptic practices. Cecil M. Lewis Jr., professor of ...
... cell is like a small city, with factoriescalled organellesdedicated ... functions. A network of intercellular "highways," called microtubules, enables ... about the cell to keep this vital machinery humming. ... Proceedings of the National Academy of Sciences sheds ...
... researchers from across the Asia-Pacific gathered today for the ... Osteoporosis Meeting, taking place at the Kuala Lumpur Convention ... Minister of Health of Malaysia, YB Datuk Rosnah bt. ... than 60 nations. His Excellency Tun Dato, Seri Utama ...
Cached Biology News:OU study suggests the bacterial ecology that lives on humans has changed in the last 100 years 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 3IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 2IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 3
... Luminescent Detection System is intended for use ... generated by an in-house validated method for ... selected target of interest. • ... is a hybridization capture assay designed to ...
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
Biology Products: